Atara Biotherapeutics (ATRA)
(Delayed Data from NSDQ)
$8.08 USD
-0.23 (-2.77%)
Updated Sep 12, 2024 04:00 PM ET
After-Market: $8.09 +0.01 (0.12%) 4:22 PM ET
3-Hold of 5 3
F Value A Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$8.08 USD
-0.23 (-2.77%)
Updated Sep 12, 2024 04:00 PM ET
After-Market: $8.09 +0.01 (0.12%) 4:22 PM ET
3-Hold of 5 3
F Value A Growth A Momentum B VGM
Zacks News
Karuna's (KRTX) KarXT Meets Primary Goal in Schizophrenia Study
by Zacks Equity Research
Data from a late-stage study shows that treatment with Karuna's (KRTX) lead candidate, KarXT, led to an early and sustained statistically significant reduction of symptoms of schizophrenia.
Esperion (ESPR) Plummets 54% Over Milestone Payment Row
by Zacks Equity Research
An SEC filing by Esperion (ESPR) reveals that partner Daiichi Sankyo disagrees with the company's assessment that cardiovascular outcome CLEAR study data would support milestone payments.
Merck's (MRK) Co-formulation Therapy Fails Lung Cancer Study
by Zacks Equity Research
Data from a mid-stage study showed that Merck's (MRK) MK-7684A did not improve progression-free survival as a potential treatment for patients with metastatic non-small cell lung cancer.
Are Medical Stocks Lagging Apexigen, Inc. (APGN) This Year?
by Zacks Equity Research
Here is how Apexigen, Inc. (APGN) and Atara Biotherapeutics (ATRA) have performed compared to their sector so far this year.
Atara Biotherapeutics (ATRA) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of -18.03% and 99.63%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Atara Biotherapeutics (ATRA) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of -5.13% and 2.13%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
BioMarin (BMRN) Hemophilia Gene Therapy BLA Gets FDA Acceptance
by Zacks Equity Research
If approved, BioMarin's (BMRN) valoctocogene roxaparvovec will become the first gene therapy for treating hemophilia A in the United States. A decision from the FDA is due on Mar 31, 2023.
Acadia (ACAD) Thrives on Nuplazid, Overdependence a Concern
by Zacks Equity Research
Acadia's (ACAD) lead drug, Nuplazid, is approved for treating hallucinations and delusions associated with Parkinson's disease psychosis. Sole dependence on Nuplazid for growth remains an overhang.
Apellis' (APLS) Empaveli Aids Growth, Stiff Competition a Woe
by Zacks Equity Research
Apellis' (APLS) lead drug, Empaveli, is approved for treating paroxysmal nocturnal hemoglobinuria. The drug's label expansion studies hold promise. Stiff competition remains an overhang.
Alnylam (ALNY) Gets FDA Approval for Oxlumo Label Expansion
by Zacks Equity Research
The FDA approves Alnylam's (ALNY) Oxlumo for treating primary hyperoxaluria type 1 to lower urinary oxalate and plasma oxalate levels in pediatric and adult patients.
Allogene (ALLO) Begins Phase II Study on Allogeneic CAR T Therapy
by Zacks Equity Research
Allogene (ALLO) starts the pivotal phase II ALPHA2 study evaluating its allogeneic CAR T therapy, ALLO-501A in patients with relapsed/refractory large B-cell lymphoma.
Acadia (ACAD) Rises More Than 14% in 3 Months: Here's Why
by Zacks Equity Research
Acadia's (ACAD) Nuplazid, approved for treating hallucinations and delusions associated with Parkinson's disease psychosis, is driving revenues. Other candidates are also making good progress.
Horizon (HZNP) Completes Enrollment in Phase IV TED Study
by Zacks Equity Research
Horizon (HZNP) completes enrollment in the phase IV study evaluating Tepezza for the treatment of thyroid eye disease in patients with a low clinical activity score.
Sanofi's (SNY) Dupixent Gets FDA Nod for Prurigo Nodularis
by Zacks Equity Research
The FDA approves Sanofi (SNY) and its partner Regeneron's Dupixent (dupilumab) for the treatment of adult patients with prurigo nodularis.
Merck's (MRK) Keytruda Gets Four New Approvals in Japan
by Zacks Equity Research
The Ministry of Health, Labour and Welfare approves Merck's (MRK) anti-PD-1 therapy, Keytruda, for four new cancer indications in Japan.
Emergent (EBS) Acquires Worldwide Rights to Smallpox Antiviral
by Zacks Equity Research
Emergent (EBS) completes the acquisition of worldwide rights to Tembexa, an FDA-approved smallpox oral antiviral for all ages, from Chimerix.
Alnylam's (ALNY) Rare Disease Drug Amvuttra Gets EC Nod
by Zacks Equity Research
The European Commission approves Alnylam's (ALNY) Amvuttra for treating hereditary transthyretin-mediated (hATTR) amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy.
Pacira (PCRX) Gets Positive CHMP View on Exparel Label Expansion
by Zacks Equity Research
The CHMP gives a positive opinion on Pacira's (PCRX) marketed drug Exparel and recommended a marketing authorization for the product to treat postsurgical pain in children aged six years or older.
Horizon's (HZNP) Phase II Sjogren's Syndrome Study Meets Goal
by Zacks Equity Research
Horizon's (HZNP) phase II study on dazodalibep for treating patients with Sjogren's syndrome meets the primary endpoint.
Acadia's (ACAD) Rett Syndrome Drug NDA Gets FDA Priority Review
by Zacks Equity Research
The FDA accepts and grants priority review to Acadia's (ACAD) NDA for trofinetide to treat Rett syndrome. A decision from the regulatory body is due on Mar 12, 2023.
IVERIC bio (ISEE) Posts Positive Top-Line Data From GA Study
by Zacks Equity Research
IVERIC bio (ISEE) reports positive top-line data from the phase III GATHER2 study, evaluating its investigational candidate, Zimura, for the treatment of geographic atrophy. Stock up.
Gilead's (GILD) Tecartus Gets EC Nod for New Cancer Indication
by Zacks Equity Research
The European Commission approves Gilead's (GILD) CAR T-cell therapy, Tecartus, for treating adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
Immunovant (IMVT) Up More Than 20% in Past 3 Months: Here's Why
by Zacks Equity Research
Immunovant's (IMVT) lead pipeline candidate, batoclimab, is being developed for treating myasthenia gravis, thyroid eye disease and other autoimmune diseases.
Immuneering (IMRX) Files IND for Cancer Candidate IMM-1-104
by Zacks Equity Research
Immuneering (IMRX) files an investigational new drug (IND) application to the FDA to start a phase I/IIa study on IMM-1-104 for the treatment of advanced RAS mutant solid tumors. Stock up.
Sanofi (SNY) Gets FDA Nod for Rare Disease Drug Xenpozyme
by Zacks Equity Research
The FDA approves Sanofi's (SNY) Xenpozyme for treating non-central nervous system (non-CNS) manifestations of acid sphingomyelinase deficiency (ASMD) disease.